JAK1 and rheumatoid arthritis: A recent post-hoc analysis of the RA-BEAM trial focussed specifically on pain outcomes.47 In RA-BEAM, a Phase 3 clinical trial of baricitinib, an oral, selective inhibitor of JAK1 and JAK2, baricitinib plus methotrexate (MTX) was associated with significant clinical improvements compared to patients treated with adalimumab plus MTX or placebo plus MTX.